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203V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 0 1 – 2 0 4nits of benefit are worth K times as much as one unit of
enefit, and this is unlikely to apply to an RR.
The author’s notation is imprecise; for example, in Equa-
ion 7 the author writes (with minor alteration):
X  exp 122
 explnRR 12SE[ln(RR)]2.
The second line cannot be true because ln(RR) and SE[ln(RR)]2
re sample estimates of population parameters, whereas the
rst line is the population mean. Again, the author is being im-
recise about epistemic and aleatory uncertainty.
Although the author is effectively proposing a frequentist
olution to his concern about the mean of the RR, from a
ayesian perspective it is not necessary to estimate the pop-
lation RR by the mean of its posterior distribution, and the
osterior median can be used as a central estimate instead [5].
ndeed, it is questionable in what sense the author’s proposal
s actually required in the context of propagating parameter
ncertainty through an economic model because parameter
ncertainty only applies in Bayesian statistics.
Finally, the author should be aware that uncertainty anal-
sis involves propagating parameter uncertainty through an
conomic model, whereas probabilistic sensitivity analysis
ntails exploring how the inputs contribute to the output un-ertainty [6].
rticle, but my first criterion is exactly what Claxton and coau-
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2004;66:751–69.ncertainty analysis is inherently Bayesian—Reply to letter
o the editor by John Stevensthank Mr. Stevens for his interest in my article [1,2]. However,
t would seem his remarks are mostly based on misunder-
tandings.
In my article, the term “effect size” is used in the epidemi-
logical sense: the effect of a medical intervention on disease
ncidence, for example. This effect size is typically expressed
s a relative risk or odds ratio. The “effect size from an eco-
omic model” would indeed not be expressed as a relative
isk, but I have never previously seen the outcome from an
conomic model being referred to as “effect size.”
Terminology in uncertainty analysis is rather fluid. The text
n the article uses “parametric bootstrap” and “Monte Carlo sim-
lation” interchangeably. “Probabilistic sensitivity analysis” is
ometimes indeed defined as assessing the contribution of the
ncertainty in inputs to the outcome uncertainty, and in fact
hat is the definition I prefer [3]. However, in many cases it is
sed interchangeably with uncertainty analysis; an example
ould be the article by Claxton et al. [4], which Mr. Stevens wants
e to refer to in my article. Incidentally, I may not have cited thathors (Sculpher and Briggs, among others) argue for [4]. This is
ot surprising because in my article I refer to the book by
riggs, Sculpher, and Claxton [5].
I don’t think I suggested that Fieller’s theorem and the ap-
roximate methods to obtain a confidence interval for an incre-
ental cost-effectiveness ratio can be used to analyze economic
odels. In addition, I do think it is abundantly clear from my
rticle that it is about sampling uncertainty only, because that is
hat is expressed by the confidence interval of a relative risk.
The complete quote from my article, with the equations, is:
When X has a Lognormal distribution with parameters
 ln(RR) and   SE[ln(RR)] then the following holds [6]:
eanX  exp 122
 explnRR 12SElnRR2.
Given the sentence immediately preceding the equations
which was omitted by Mr. Stevens), the second line is math-
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204 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 0 1 – 2 0 4matically identical to the first, and I fail to see how the first
an be true while the second is not.
The remainder of the comment by Mr. Stevens may be an
ttempt to draw the article into the futile war of words be-
ween frequentists and Bayesians. Parameter uncertainty in-
eed applies in Bayesian and not in frequentist statistics, but
conomic models have to deal with uncertainty, whether the
urveyor is a frequentist or a Bayesian.
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